MedTrace Logo

Cerebral Autoregulation Guiding Blood Pressure Management After Revascularization

NCT05670028 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-01-05

No results posted yet for this study

Summary

This clinical trial aims to learn whether blood pressure (BP) guided by individualized cerebral autoregulation (CA) is safe and provides a better prognosis than a fixed target in patients with ischemic stroke after endovascular therapy. The BP of participants will be managed at least 48 hours after revascularization. Researchers will compare the CA-guided BP group with the fixed target BP group to mainly see if individualized BP could help more patients to have their neurological function improved at seven days.

Conditions

  • Ischemic Stroke
  • Revascularization
  • Blood Pressure
  • Cerebrovascular Insufficiency
  • Cerebral Autoregulation
  • Individuation
  • Hemorrhagic Transformation Due to Acute Stroke

Interventions

DRUG

Hypotensive Drugs and/or Vasoactive Drugs

To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or vasoactive drugs (noradrenaline or dopamine).

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-04
Primary Completion
2026-01-31
Completion
2026-06-04

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05670028 on ClinicalTrials.gov